Newroom

We are happy to share great news! SUL-238 is currently in Phase I clinical trials in collaboration with our Turkish partner GEN Ilac. It is the first drug reported that leads to persisting improvement of vascular aging. This work has recently been...

We are excited to announce that our lead drug candidate SUL-238 has been featured in the prestigious journal Nature Medicine. The article highlights hibernation as a source of inspiration for drug development, which also forms the basis for our...

https://open.spotify.com/episode/7sC62GDjmc0g2oQFu4XZo0

Wintersleep or hibernation is used by some animals to survive harsh environmental conditions, but not all animals can hibernate. Interestingly, hibernators possess protective mechanisms that allows them to withstand or repair cell and organ damage...

Sulfateq is happy to announce that a new scientific manuscript detailing the safety of SUL-138 is published in the leading journal Toxicology Reports. This manuscript details the safety, tolerability and toxicokinetic data of SUL-138, an obligatory...